Abstract
This review discusses about identification and characterization of biomarkers in brain cancer utilizing proteomic analysis which is a powerful tool for the discovery of cancer molecular markers. Proteomic analysis allows the characterization of proteins at pictogram level with mass spectrometry (MS) and changes in the levels inherent to the pathophysiology of any cell type, tissue, or whole organism. Protein markers identified by this approach could discriminate cancerous from normal cells. As demonstrated here, proteomic analysis may be efficiently used to identify new indicators for the diagnosis and prognosis of cancer progression. The 2D-DIGE method has been one of the mainstream technologies used for proteomic investigations. In this method, proteins are separated in the first dimension according to charge by isoelectric focusing, followed by separation in the second dimension according to molecular weight, using polyacrylamide gel electrophoresis. Using this approach, up to 1,000 protein spots could be separated and visualized in a single experiment. Gels of different samples are compared and analyzed using computer software, and differentially expressed protein spots are then excised and identified using MS. In this manuscript, we reviewed the relevance of biomarkers in brain cancers and cancer proteomics and the possibility of application of 2D-DIGE-MS method in discovery of potential biomarkers in brain cancers especially glioblastoma multiforme (GBM) which has high rate of recurrence and resistance to chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
References
Banerjee HN, Mahaffey K, Riddick E, Banerjee A, Bhowmik N, Patra M. Search for a diagnostic/prognostic biomarker for the brain cancer glioblastoma multiforme by 2D-DIGE-MS technique. Mol Cell Biochem. 2012;367:59–63.
Collet B, Guitton N, Saïkali S, Avril T, Pineau C, Hamlat A, Mosser J, Quillien V. Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach. Proteome Sci. 2011;9:5956–9.
Diede SJ. TERT hypermethylation: biomarker in paediatric brain tumors. Lancet Oncol. 2013;14:447–8.
Dokic I, Hartmann C, Herold-Mende C, Régnier-Vigouroux A. Glutathione peroxidase 1 activity dictates the sensitivity of glioblastoma cells to oxidative stress. Glia. 2012;60:1785–800.
Epstein MG, Reeves BD, Matty WS, et al. Enhanced sensitivity employing zwitterionic and pI balancing dyes (Z-CyDyes) optimized for 2-D gel electrophoresis based on side chain modifications of CyDye fluorophores. New tools for use in proteomics and diagnostics. Bioconjug Chem. 2013;24:1552–61.
Kang Y, Techanukul T, Mantalaris A, et al. Comparison of three commercially available DIGE analysis software packages: minimal user intervention in gel-based proteomics. J Proteome Res. 2009;8:1077–84.
Kool M, Korshunoy A, Pfister SM. Update on molecular and genetic alterations in adult medulloblastoma. Memo. 2012;5:228–32.
Lemee JM, Com E, Clavreul A, et al. Proteomic analysis of glioblastomas: what is the best brain control sample? J Proteomics. 2013;85:165–73.
McNight TR, Smith KJ, Chu PW, et al. Choline metabolism, proliferation, and angiogenesis in nonenhancing grades 2 and 3 astrocytoma. J Magn Reson Imaging. 2011;33:808–16.
Melchior K, Tholey A, Heisel S, Keller A, Lenhof HP, Meese E, et al. Proteomic study of human glioblastoma multiforme tissue employing complementary two-dimensional liquid chromatography- and mass spectrometry-based approaches. J Proteome Res. 2009;8:4604–14.
Moskal JR, Kroes RA, Dawson G. The glycobiology of brain tumors: disease relevance and therapeutic potential. Expert Rev Neurother. 2009;9:1529–45.
Pan X, Willim M, Mirbahai L, et al. In vitro metabonomic study detects increases in UDP- GlcNAc and UDP- GalNAc, as early phase markers of cisplatin treatment response in brain tumor cells. J Proteome Res. 2011;10:3493–500.
Thakkar D, Shervington L, Shervington A. Proteomic studies coupled with RNAi methodologies can shed further light on the downstream effects of telomerase in glioma. Cancer Invest. 2011;29:113–22.
Verma M. Epigenetic biomarkers in cancer epidemiology. Methods Mol Biol. 2012;863:467–80.
Verma M, Khoury MJ, Ioannidis JP. Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic and telomerase profiling. Cancer Epidemiol Biomarkers Prev. 2013;22:189–200.
Wade A, Robinson AE, Engler JR, et al. Proteoglycans and their role in brain cancer. FEBS J. 2013;280:2399–417.
Wei P, Zhang W, Yang LS, et al. Serum GFAP autoantibody as an ELISA-detectable glioma marker. Tumour Biol. 2013;34:2283–92.
Yang S, Nam Y, Kim MO, et al. Computer-aided detection of metastatic brain tumors using magnetic resonance black-blood imaging. Invest Radiol. 2013;48:113–9.
Yurtsever A, Haydaroglu A, Biray-Avci C, et al. Assessment of genetic markers and glioblastoma stem-like cells in activation of dendritic cells. Hum Cell. 2013;26:105–13.
Zanini C, Mandilli G, Pulera F, et al. Analysis of different medulloblastoma histotypes by two-dimensional gel and MALDI-TOF. Childs Nerv Syst. 2011;27:2077–83.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media Dordrecht
About this entry
Cite this entry
Banerjee, H.N., Verma, M. (2015). Using 2D-DIGE-MS to Identify Biomarkers for Brain Cancer. In: Preedy, V., Patel, V. (eds) Biomarkers in Cancer. Biomarkers in Disease: Methods, Discoveries and Applications. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7681-4_22
Download citation
DOI: https://doi.org/10.1007/978-94-007-7681-4_22
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-7680-7
Online ISBN: 978-94-007-7681-4
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences